Hidradenitis Suppurativa - Pipeline Review, H2 2018

  • ID: 4592431
  • Report
  • 124 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • ChemoCentryx Inc
  • Fresenius SE & Co KGaA
  • Incyte Corp
  • Novartis AG
  • UCB SA
  • MORE
Hidradenitis Suppurativa - Pipeline Review, H2 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Hidradenitis Suppurativa - Pipeline Review, H2 2018, provides an overview of the Hidradenitis Suppurativa (Dermatology) pipeline landscape.

Hidradenitis suppurativa is a chronic skin condition that features pea-sized to marble-sized lumps under the skin. Also known as acne inversa, these deep-seated lumps typically develop where skin rubs together such as the armpits, groin, between the buttocks and under the breasts.

Report Highlights:

This latest pipeline guide Hidradenitis Suppurativa - Pipeline Review, H2 2018, provides comprehensive information on the therapeutics under development for Hidradenitis Suppurativa (Dermatology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Hidradenitis Suppurativa (Dermatology) pipeline guide also reviews of key players involved in therapeutic development for Hidradenitis Suppurativa and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 2, 1, 5, 2, 3 and 3 respectively.

Hidradenitis Suppurativa (Dermatology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Hidradenitis Suppurativa (Dermatology).
  • The pipeline guide reviews pipeline therapeutics for Hidradenitis Suppurativa (Dermatology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Hidradenitis Suppurativa (Dermatology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Hidradenitis Suppurativa (Dermatology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Hidradenitis Suppurativa (Dermatology)
Reasons for Purchase:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Hidradenitis Suppurativa (Dermatology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Hidradenitis Suppurativa (Dermatology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • AbbVie Inc
  • ChemoCentryx Inc
  • Fresenius SE & Co KGaA
  • Incyte Corp
  • Novartis AG
  • UCB SA
  • MORE
Introduction

Report Coverage

Hidradenitis Suppurativa - Overview

Hidradenitis Suppurativa - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Products under Development by Companies

Hidradenitis Suppurativa - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Hidradenitis Suppurativa - Companies Involved in Therapeutics Development

AbbVie Inc

Celgene Corp

ChemoCentryx Inc

Coherus BioSciences Inc

Fresenius SE & Co KGaA

Immunwork Inc

Incyte Corp

InflaRx NV

Innovation Pharmaceuticals Inc

Novartis AG

Sandoz International GmbH

UCB SA

XBiotech Inc

Hidradenitis Suppurativa - Drug Profiles

ABBV-3373 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

adalimumab biosimilar - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

apremilast - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

avacopan - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

bimekizumab - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

brilacidin tetrahydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CJM-112 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

IFX-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

INCB-54707 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TE-2232 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Xilonix - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Hidradenitis Suppurativa - Dormant Projects

Hidradenitis Suppurativa - Discontinued Products

Hidradenitis Suppurativa - Product Development Milestones

Featured News & Press Releases

Jul 10, 2018: XBiotech Announces First Patient in Phase 2 Study Evaluating Subcutaneous MABp1 in Patients with Hidradenitis Suppurativa

Jun 05, 2018: InflaRx Opens New Research Facility in Ann Arbor

May 31, 2018: Sandoz receives positive CHMP opinion for Halimatoz

May 31, 2018: Sandoz receives positive CHMP opinion for Hyrimoz

Apr 16, 2018: XBiotech Announces Upcoming Phase 2 Clinical Studies in Dermatology

Apr 05, 2018: AbbVie Announces Global Resolution of HUMIRA (adalimumab) Patent Disputes with Samsung Bioepis

Mar 08, 2018: InflaRx announces first patient enrolled in Phase IIb trial with lead candidate IFX-1 in Hidradenitis Suppurativa

Feb 21, 2018: Canadians living with Moderate to Severe Hidradenitis Suppurativa are beginning to have public access to HUMIRA (Adalimumab) to manage their disease

Feb 12, 2018: AbbVie to Present Data on HUMIRA at 2018 American Academy of Dermatology Annual Meeting

Jan 26, 2018: XBiotech Announces Presentation of Data from Phase 2 Study Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Jan 19, 2018: XBiotech Announces Presentation of Phase 2 Open Label Extension Study Data Evaluating MABp1 for the Treatment of Hidradenitis Suppurativa

Jan 09, 2018: InflaRx Receives IND Acceptance To Proceed With A Phase IIb Trial With Lead Candidate IFX-1 In Hidradenitis Suppurativa

Dec 04, 2017: XBiotech Announces Publication of Phase II Data From Hidradenitis Suppurativa Phase II Study in The Journal of Investigative Dermatology

Oct 31, 2017: Innovation Pharma Provides Update on Brilacidin

Oct 03, 2017: XBiotech Announces Addition of Renowned Dermatologist Dr. William Levis to its Scientific Advisory Board

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Hidradenitis Suppurativa, H2 2018

Number of Products under Development by Companies, H2 2018

Products under Development by Companies, H2 2018

Number of Products by Stage and Target, H2 2018

Number of Products by Stage and Mechanism of Action, H2 2018

Number of Products by Stage and Route of Administration, H2 2018

Number of Products by Stage and Molecule Type, H2 2018

Hidradenitis Suppurativa - Pipeline by AbbVie Inc, H2 2018

Hidradenitis Suppurativa - Pipeline by Celgene Corp, H2 2018

Hidradenitis Suppurativa - Pipeline by ChemoCentryx Inc, H2 2018

Hidradenitis Suppurativa - Pipeline by Coherus BioSciences Inc, H2 2018

Hidradenitis Suppurativa - Pipeline by Fresenius SE & Co KGaA, H2 2018

Hidradenitis Suppurativa - Pipeline by Immunwork Inc, H2 2018

Hidradenitis Suppurativa - Pipeline by Incyte Corp, H2 2018

Hidradenitis Suppurativa - Pipeline by InflaRx NV, H2 2018

Hidradenitis Suppurativa - Pipeline by Innovation Pharmaceuticals Inc, H2 2018

Hidradenitis Suppurativa - Pipeline by Novartis AG, H2 2018

Hidradenitis Suppurativa - Pipeline by Sandoz International GmbH, H2 2018

Hidradenitis Suppurativa - Pipeline by UCB SA, H2 2018

Hidradenitis Suppurativa - Pipeline by XBiotech Inc, H2 2018

Hidradenitis Suppurativa - Dormant Projects, H2 2018

Hidradenitis Suppurativa - Discontinued Products, H2 2018

List of Figures

Number of Products under Development for Hidradenitis Suppurativa, H2 2018

Number of Products under Development by Companies, H2 2018

Number of Products by Top 10 Targets, H2 2018

Number of Products by Stage and Top 10 Targets, H2 2018

Number of Products by Top 10 Mechanism of Actions, H2 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H2 2018

Number of Products by Routes of Administration, H2 2018

Number of Products by Stage and Routes of Administration, H2 2018

Number of Products by Molecule Types, H2 2018

Number of Products by Stage and Molecule Types, H2
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
  • AbbVie Inc
  • Celgene Corp
  • ChemoCentryx Inc
  • Coherus BioSciences Inc
  • Fresenius SE & Co KGaA
  • Immunwork Inc
  • Incyte Corp
  • InflaRx NV
  • Innovation Pharmaceuticals Inc
  • Novartis AG
  • Sandoz International GmbH
  • UCB SA
  • XBiotech Inc
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll